

21. Gosselin RC, Adcock DM, Bates SM, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. *Thromb Haemost.* 2018;118(3):437-450.
22. Wright C, Brown R, Cuker A. Laboratory measurement of the direct oral anticoagulants: Indications and impact on management in clinical practice. *Int J Lab Hematol.* 2017; 39 Suppl 1:31-36.
23. Douxfils J, Adcock DM, Bates SM, et al. 2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. *Thromb Haemost.* 2021;121(8):1008-1020.
24. Penka M, Novotný J. Co lze očekávat od monitoringu DOACs. *Interv Akut Kardiol.* 2020;19(4):215-221.
25. Edwina AE, Dia N, Dreesen E, et al. Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review. *Clin Pharmacokinet.* 2023;62(3):351-373.
26. Liu Z, Xie Q, Xiang Q, et al. Anti-FXa-IIa activity test in Asian and its potential role for drug adherence evaluation in patients with direct oral anticoagulants: a nationwide multi-center synchronization study. *Cardiovasc Diagn Ther.* 2020;10(5):1293-1302.
27. Alalawneh M, Awaisu A, Rachid O. Rivaroxaban Pharmacokinetics in Obese Subjects: A Systematic Review. *Clin Pharmacokinet.* 2022;61(12):1677-1695.
28. Gregorová J, Tašková I, et al. Antikoagulační terapie. Maxdorf. 2022. ISBN 978-80-7345-728-0.
29. Moner-Banet T, Alberio L, Bart PA. Does One Dose Really Fit All? On the Monitoring of Direct Oral Anticoagulants: A Review of the Literature. *Hamostaseologie.* 2020;40(2):184-200.
30. Patel JP, Byrne RA, Patel RK, et al. Progress in the monitoring of direct oral anticoagulant therapy. *Br J Haematol.* 2019;184(6):912-924.
31. Rottenstreich A, Zacks N, Kleinstern G, et al. Direct-acting oral anticoagulant drug level monitoring in clinical patient management. *J Thromb Thrombolysis.* 2018;45(4):543-549.
32. Šinigoj P, Malmström RE, Vene N et al. Dabigatran Concentration: Variability and Potential Bleeding Prediction In „Real-Life“ Patients With Atrial Fibrillation. *Basic Clin Pharmacol Toxicol.* 2015;117(5):323-329.
33. Skeppholm M, Hjemdahl P, Antovic JP, et al. On the monitoring of dabigatran treatment in „real life“ patients with atrial fibrillation. *Thromb Res.* 2014;134(4):783-789.
34. Kaserer A, Schedler A, Jetter A, et al. Risk Factors for Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life Patients. *Thromb Haemost.* 2018;118(5):808-817.
35. Sin CF, Wong KP, Wong TF, et al. Plasma apixaban levels in Chinese patients with chronic kidney disease-Relationship with renal function and bleeding complications. *Front Pharmacol.* 2022;13:928401.
36. Hu YF, Liao JN, Chern CM, et al. Identification and management of noncompliance in atrial fibrillation patients receiving dabigatran: the role of a drug monitor. *Pacing Clin Electrophysiol.* 2015;38(4):465-471.
37. Schnierer M, Samoš M, Bolek T et al. The Effect of Proton Pump Inhibitor Withdrawal on Dabigatran Etxilate Plasma Levels in Patients With Atrial Fibrillation: A Washout Study. *J Cardiovasc Pharmacol.* 2020;75(4):333-335.
38. Wongcharoen W, Pacharasupa P, Norasetthada L, et al. Anti-Factor Xa Activity of Standard and Japan-Specific Doses of Rivaroxaban in Thai Patients With Non-Valvular Atrial Fibrillation. *Circ J.* 2020;84(7):1075-1082.
39. Martin AC, Thomas W, Mahir Z, et al. Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study. *Thromb Haemost.* 2021;121(2):224-233.
40. Speed V, Green B, Roberts LN, et al. Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis. *J Thromb Haemost.* 2020; 18(9):2296-2307.
41. Piran S, Traquair H, Chan N, et al. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study. *Res Pract Thromb Haemost.* 2018;2(4):684-688.
42. Kim JH, Shelat N, Ji CS. Apixaban and Rivaroxaban Anti-Xa Concentration Utilization in Clinical Practice. *J Cardiovasc Pharmacol.* 2023; 81(2):165-170.
43. Sennesael AL, Larock AS, Hainaut P, et al. The Impact of Strong Inducers on Direct Oral Anticoagulant Levels. *Am J Med.* 2021;134(10):1295-1299.
44. Škorňová I, Samoš M, Bolek T, et al. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation? *Pharmacol Res Perspect.* 2021; 9(3):e00730.
45. Camporese G, Bernardi D, Bernardi E, et al. Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation. *Vascul Pharmacol.* 2020;130:106682.
46. Perlman A, Hochberg-Klein S, Choshen Cohen L, et al. Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. *J Thromb Thrombolysis.* 2019;47(4):590-595.
47. Suwa M, Morii I, Kino M. Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation – Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. *Circ J.* 2019;83(5):991-999.
48. Chang M, Yu Z, Shenker A, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. *J Clin Pharmacol.* 2016;56(5):637-645.
49. Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. *J Clin Pharmacol.* 2016;56(5):628-636.
50. Frost C, Shenker A, Gandhi MD, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. *Br J Clin Pharmacol.* 2014;78(4):877-885.
51. Wasan SM, Feland N, Grant R, et al. Validation of apixaban anti-factor Xa assay and impact of body weight. *Thromb Res.* 2019;182:51-55.
52. Testa S, Prandoni P, Paoletti O, et al. Direct oral anticoagulant plasma levels' striking increase in severe COVID-19 respiratory syndrome patients treated with antiviral agents: The Cremona experience. *J Thromb Haemost.* 2020;18(6):1320-1323.
53. Magnocavallo M, Bellasi A, Mariani MV, et al. Thromboembolic and Bleeding Risk in Atrial Fibrillation Patients with Chronic Kidney Disease: Role of Anticoagulation Therapy. *J Clin Med.* 2020;10(1).
54. Thompson LE, Davis BH, Narayan R, et al. Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics. *Clin Pharmacol Ther.* 2023;113(3):585-599.
55. Hinojar R, Jiménez-Natcher JJ, Fernández-Golfín C, et al. New oral anticoagulants: a practical guide for physicians. *Eur Heart J Cardiovasc Pharmacother.* 2015;1(2):134-145.
56. Pradaxa – Souhrn údajů o přípravku. [cit. 2023–06–05]. Available from: WWW: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_cs.pdf
57. Rota E, Testa L, Di Brigida G, et al. The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm. *J Thromb Thrombolysis.* 2020;50(3):732-738.
58. Limdi NA, Beasley TM, Sun J, et al. Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function. *Clin Pharmacol Ther.* 2021;109(6):1593-1605.
59. Chatterjee S, Sardar P, Giri JS, et al. Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients. *Mayo Clin Proc.* 2014;89(7):896-907.
60. Eliquis – Souhrn údajů o přípravku. [cit. 2023–06–30]. Available from: WWW: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_cs.pdf
61. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *J Am Coll Cardiol.* 2014;63(4):321-328.
62. Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: Observations from the ARISTOTLE trial. *Eur Heart J.* 2014;35(28):1864-1872.
63. Xue QL. The frailty syndrome: definition and natural history. *Clin Geriatr Med.* 2011; 27(1):1-15.
64. Committee for Medicinal Products for Human Use. Reflection paper on physical frailty: instruments for baseline characterisation of older populations in clinical trials [Internet].
65. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. *Age Ageing.* 2010;39(4):412-423.
66. Park CS, Choi EK, Kim HM, et al. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. *Heart Rhythm.* 2017;14(4):501-507.
67. Topinková E, Berková M, Mádllová P, et al. „Krátká baterie pro testování fyzické zdatnosti seniorů“ a její využití pro diagnózu geriatrické křehkosti v klinické praxi. *Geriatrica a Gerontologie* 2013;2(1):43-49.
68. Verrest L, Wilthagen EA, Beijnen JH, et al. Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. *Clin Pharmacokinet.* 2021;60(9):1149-1169.
69. Andrade J, Khairy P, Dobrev D et al. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. *Circ Res.* 2014;114(9):1453-1468.
70. Zhao Y, Guo M, Li D, et al. Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review. *Clin Appl Thromb Hemost.* 2023;29:10760296231153638.
71. Russo V, Cattaneo D, Giannetti L, et al. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity. *Clin Ther.* 2021; 43(9):e255-e263.
72. Martin KA, Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. *J Thromb Haemost.* 2021;19(8):1874-1882.
73. Malá-Ládová K, Voříšková E, Košťálová B, et al. Terminologie adherence k léčbě – prvotní konsenzuální překlad pomocí Delphi metody. *Vnitř Lék.* 2022;68(E-2):22-28.

Další literatura u autora
a na www.casopisvnitrnilekarstvi.cz